Dermira (NASDAQ:DERM) Downgraded to Hold at BidaskClub

BidaskClub cut shares of Dermira (NASDAQ:DERM) from a buy rating to a hold rating in a research note published on Tuesday, January 9th.

DERM has been the topic of a number of other research reports. Cantor Fitzgerald set a $45.00 price target on Dermira and gave the company a buy rating in a research note on Wednesday, November 29th. Needham & Company LLC reissued a buy rating and issued a $46.00 price target on shares of Dermira in a research note on Sunday, September 17th. Guggenheim assumed coverage on Dermira in a research note on Tuesday, December 5th. They issued a buy rating on the stock. Mizuho cut their price target on Dermira from $43.00 to $39.00 and set a buy rating on the stock in a research note on Tuesday, December 12th. Finally, Leerink Swann reissued an outperform rating and issued a $41.00 price target (down previously from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Dermira has a consensus rating of Hold and an average price target of $42.17.

Shares of Dermira (DERM) traded up $0.23 on Tuesday, reaching $28.21. The company’s stock had a trading volume of 394,052 shares, compared to its average volume of 579,905. The company has a market cap of $1,190.00, a price-to-earnings ratio of -4.53 and a beta of 0.80. The company has a debt-to-equity ratio of 1.40, a current ratio of 4.68 and a quick ratio of 4.68. Dermira has a 52-week low of $21.35 and a 52-week high of $38.75.

Dermira (NASDAQ:DERM) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.12) by ($0.09). Dermira had a negative net margin of 992.18% and a negative return on equity of 41.22%. equities analysts forecast that Dermira will post -7.36 earnings per share for the current fiscal year.

In other Dermira news, SVP Christopher M. Griffith sold 18,458 shares of Dermira stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total value of $499,288.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eugene A. Bauer sold 3,000 shares of Dermira stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $27.34, for a total value of $82,020.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,258 shares of company stock worth $985,873 in the last ninety days. 13.30% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in DERM. Schwab Charles Investment Management Inc. raised its stake in shares of Dermira by 24.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 140,495 shares of the biopharmaceutical company’s stock valued at $4,095,000 after purchasing an additional 27,259 shares during the period. First Trust Advisors LP bought a new position in shares of Dermira in the 2nd quarter valued at about $1,174,000. Rhumbline Advisers grew its holdings in shares of Dermira by 57.1% in the 2nd quarter. Rhumbline Advisers now owns 43,781 shares of the biopharmaceutical company’s stock valued at $1,276,000 after acquiring an additional 15,905 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 2,203 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Dermira by 40.9% in the 2nd quarter. Legal & General Group Plc now owns 9,664 shares of the biopharmaceutical company’s stock valued at $281,000 after acquiring an additional 2,803 shares in the last quarter. 99.47% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://weekherald.com/2018/01/20/dermira-derm-rating-lowered-to-hold-at-bidaskclub.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply